Injection technique and individual characteristics associated with local reactogenicity to quadrivalent human papillomavirus vaccine in young women

Trial Profile

Injection technique and individual characteristics associated with local reactogenicity to quadrivalent human papillomavirus vaccine in young women

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Adverse reactions
  • Acronyms FAR Trial
  • Most Recent Events

    • 06 Sep 2012 Status changed from recruiting to completed as reported by Australian New Zealand Clinical Trials Registry record.
    • 18 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top